Current Ratio
since 2005
Calculation
Celgene Corp., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2018 | 2.23 | = | 9,067) | ÷ | 4,057) |
| Dec 31, 2017 | 4.99 | = | 14,892) | ÷ | 2,987) |
| Dec 31, 2016 | 3.67 | = | 10,868) | ÷ | 2,959) |
| Dec 31, 2015 | 4.77 | = | 9,401) | ÷ | 1,969) |
| Dec 31, 2014 | 4.60 | = | 9,713) | ÷ | 2,112) |
| Dec 31, 2013 | 3.88 | = | 7,551) | ÷ | 1,946) |
| Dec 31, 2012 | 3.27 | = | 5,534) | ÷ | 1,690) |
| Dec 31, 2011 | 2.83 | = | 4,353) | ÷ | 1,540) |
| Dec 31, 2010 | 4.06 | = | 4,343) | ÷ | 1,070) |
| Dec 31, 2009 | 7.77 | = | 3,845) | ÷ | 495) |
| Dec 31, 2008 | 5.39 | = | 2,841) | ÷ | 527) |
| Dec 31, 2007 | 7.12 | = | 3,084) | ÷ | 433) |
| Dec 31, 2006 | 9.64 | = | 2,311) | ÷ | 240) |
| Dec 31, 2005 | 7.17 | = | 973) | ÷ | 136) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
Comparison to Competitors
Celgene Corp., current ratio, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 2.23 | 0.98 | 2.79 | 1.61 | 1.47 | 1.73 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 1.73 |
| Dec 31, 2017 | 4.99 | 1.28 | 5.49 | 1.55 | 1.43 | 1.32 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 1.34 |
| Dec 31, 2016 | 3.67 | 1.65 | 4.11 | 1.55 | 0.97 | 1.37 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 1.44 |
| Dec 31, 2015 | 4.77 | 1.50 | 4.44 | 1.30 | 1.27 | 1.53 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 1.38 |
| Dec 31, 2014 | 4.60 | 1.41 | 4.95 | 1.73 | 1.75 | 1.09 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 1.22 |
| Dec 31, 2013 | 3.88 | 2.59 | 3.44 | 1.52 | 2.01 | 1.47 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.16 |
| Dec 31, 2012 | 3.27 | 2.27 | 3.81 | 1.15 | 1.80 | 1.55 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 2.31 |
| Dec 31, 2011 | 2.83 | — | 4.80 | 1.97 | 1.50 | 1.60 | 5.53 | 2.38 | 2.04 | 2.06 | 4.40 | 1.55 |
| Dec 31, 2010 | 4.06 | — | 3.52 | 1.97 | 1.73 | 2.09 | 2.32 | 2.05 | 1.86 | 2.11 | 3.28 | 2.42 |
| Dec 31, 2009 | 7.77 | — | 4.89 | 2.21 | 1.89 | 1.90 | 2.57 | 1.82 | 1.80 | 1.66 | 4.55 | 2.76 |
| Dec 31, 2008 | 5.39 | — | 3.12 | 2.20 | 1.53 | 0.95 | 3.52 | 1.65 | 1.35 | 1.59 | 6.23 | 2.82 |
| Dec 31, 2007 | 7.12 | — | 2.11 | 1.20 | 1.40 | 2.33 | 4.11 | 1.51 | 1.23 | 2.15 | 2.81 | 1.93 |
| Dec 31, 2006 | 9.64 | — | 1.67 | 1.59 | 1.38 | 1.91 | 3.18 | 1.20 | 1.20 | 2.20 | 10.44 | 1.70 |
| Dec 31, 2005 | 7.17 | — | 2.57 | 1.78 | 1.30 | 1.89 | 6.79 | 2.48 | 1.58 | 1.47 | 8.46 | 1.71 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 2.23 | 1.70 |
| Dec 31, 2017 | 4.99 | 1.73 |
| Dec 31, 2016 | 3.67 | 1.91 |
| Dec 31, 2015 | 4.77 | 1.90 |
| Dec 31, 2014 | 4.60 | 2.18 |
| Dec 31, 2013 | 3.88 | 2.16 |
| Dec 31, 2012 | 3.27 | 2.04 |
| Dec 31, 2011 | 2.83 | 2.29 |
| Dec 31, 2010 | 4.06 | 2.14 |
| Dec 31, 2009 | 7.77 | 1.94 |
| Dec 31, 2008 | 5.39 | 1.65 |
| Dec 31, 2007 | 7.12 | 1.74 |
| Dec 31, 2006 | 9.64 | 1.64 |
| Dec 31, 2005 | 7.17 | 1.81 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., current ratio, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 2.23 | 1.38 |
| Dec 31, 2017 | 4.99 | 1.47 |
| Dec 31, 2016 | 3.67 | 1.68 |
| Dec 31, 2015 | 4.77 | 1.67 |
| Dec 31, 2014 | 4.60 | 1.87 |
| Dec 31, 2013 | 3.88 | 1.93 |
| Dec 31, 2012 | 3.27 | 1.81 |
| Dec 31, 2011 | 2.83 | 1.91 |
| Dec 31, 2010 | 4.06 | 1.80 |
| Dec 31, 2009 | 7.77 | 1.75 |
| Dec 31, 2008 | 5.39 | 1.42 |
| Dec 31, 2007 | 7.12 | 1.51 |
| Dec 31, 2006 | 9.64 | 1.39 |
| Dec 31, 2005 | 7.17 | 1.63 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).